No recent analyst price targets found for TDI.
Latest News for TDI
5 International ETFs Up at Least 20% in 2026 & Beating the S&P 500
International ETFs are outperforming the S&P 500 in 2026, led by strong gains across Asian and global markets. Here are five ETFs to watch.
Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Pharmaceutical
GV101, a novel, highly selective ROCK2 inhibitor, yielded an 86.2% best overall response rate (bORR) at 400 mg and a 67.9% bORR at 200 mg at 24 weeks in chronic Graft versus Host Disease (cGvHD) patients who had failed at least two prior lines of therapy. GV101's 24-week bORR exceeds published 6-month bORRs for all existing, approved steroid-refractory cGvHD therapies.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TDI.
U.S. House Trading
No House trades found for TDI.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.